Destination XL Group, Inc., including its various subsidiaries, specializes in retailing apparel and footwear designed for big and tall men across both the United States and Canada. Their diverse product assortment encompasses sportswear, formal attire, and everyday casual wear. This includes essential items like jeans, casual trousers, t-shirts, polo shirts, dress shirts, and suit components. Furthermore, the company supplies tailored pieces such as blazers, formal trousers, dress shirts, and neckties, alongside vintage-themed graphic t-shirts and woven garments, often marketed under their proprietary brands. These products are sold under several recognized trade names, including Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. As of January 29, 2022, the company maintained a significant retail presence, operating 220 DXL retail locations, 16 DXL outlet stores, 35 Casual Male XL retail stores, and 19 Casual Male XL outlet stores. Beyond brick-and-mortar, it also reaches customers through its dxl.com e-commerce platform, m.destinationXL.com mobile site, and a dedicated mobile application. The corporation, initially incorporated in 1976 and headquartered in Canton, Massachusetts, adopted its current name, Destination XL Group, Inc., in February 2013, having previously operated as Casual Male Retail Group, Inc.
Destination XL Group, Inc. Reports Second Quarter Financial Results
Destination XL posted Q2 fiscal 2026 sales of $111.6 million, down 3.4% year over year, with comparable sales down 3.5% as traffic stayed under pressure. Net income swung to $2.0 million, or $0.04 per diluted share, from a year-ago loss, helped by a one-time $4.6 million tariff refund, and adjusted EBITDA rose to $7.7 million from $4.7 million.
The bigger news is that the DXL Board concluded the pending merger with FullBeauty is no longer advisable and not in stockholders' best interests, citing FullBeauty's declining operating performance, increased indebtedness, potential negative equity value, and the substantial dilution the deal would impose. The Board is urging stockholders to vote AGAINST the issuance proposal, effectively blocking the transaction.
Comparable sales improved sequentially from down 5.7% in May to down 2.8% in June and down 1.9% in July, though management repeated that GLP-1 weight-loss medications are driving structural changes in Big + Tall category demand.
Liquidity thinned to $20.1 million in cash and investments from $33.5 million a year ago, with no debt and negative free cash flow of $8.7 million for the first six months; fiscal 2026 capex guidance was cut to $8-10 million.